NAMD
Clinical trials for NAMD explained in plain language.
Never miss a new study
Get alerted when new NAMD trials appear
Sign up with your email to follow new studies for NAMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug aims to offer cheaper option for blinding disease
Disease control Recruiting nowThis phase 3 trial tests whether a new drug called ABP 938 works as well as the approved treatment Eylea HD for wet age-related macular degeneration, a leading cause of vision loss. About 304 people aged 50 and older with untreated wet AMD will receive injections of either drug i…
Matched conditions: NAMD
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Eye implant could replace monthly shots for blinding disease
Disease control Recruiting nowThis study tests a small, refillable implant placed in the eye that slowly releases medication for wet age-related macular degeneration (nAMD). It aims to see if refilling the implant every 24 weeks works as well as getting a standard eye injection every 4 weeks. About 68 Chinese…
Matched conditions: NAMD
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
One-Shot gene therapy could end monthly eye injections for wet AMD
Disease control Recruiting nowThis study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 714 adults aged 50-89 who currently need regular eye injections will receive either the gene therapy or standard treatment. The goal is to…
Matched conditions: NAMD
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New eye drug SCT520FF hopes to tackle wet AMD
Disease control Recruiting nowThis study tests an experimental drug called SCT520FF for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 82 adults aged 45 to 80 will receive either SCT520FF or an existing treatment (EYLEA) via eye injections. Researchers will check safety, sid…
Matched conditions: NAMD
Phase: PHASE1, PHASE2 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 26, 2026 14:00 UTC